ATE472609T1 - Kombinatorische bibliotheken von monomerdomänen - Google Patents

Kombinatorische bibliotheken von monomerdomänen

Info

Publication number
ATE472609T1
ATE472609T1 AT02725828T AT02725828T ATE472609T1 AT E472609 T1 ATE472609 T1 AT E472609T1 AT 02725828 T AT02725828 T AT 02725828T AT 02725828 T AT02725828 T AT 02725828T AT E472609 T1 ATE472609 T1 AT E472609T1
Authority
AT
Austria
Prior art keywords
domains
multimers
immuno
monomer
methods
Prior art date
Application number
AT02725828T
Other languages
English (en)
Inventor
Joost Kolkman
Willem Stemmer
Original Assignee
Amgen Mountain View Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Mountain View Inc filed Critical Amgen Mountain View Inc
Application granted granted Critical
Publication of ATE472609T1 publication Critical patent/ATE472609T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00—Methods of screening libraries
    • C40B30/04—Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C07K1/047—Simultaneous synthesis of different peptide species; Peptide libraries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00583—Features relative to the processes being carried out
    • B01J2219/00603—Making arrays on substantially continuous surfaces
    • B01J2219/00659—Two-dimensional arrays
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/0068—Means for controlling the apparatus of the process
    • B01J2219/00702—Processes involving means for analysing and characterising the products
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00718—Type of compounds synthesised
    • B01J2219/0072—Organic compounds
    • B01J2219/00725—Peptides
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/10—Libraries containing peptides or polypeptides, or derivatives thereof

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Food Science & Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Polymerisation Methods In General (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
AT02725828T 2001-04-26 2002-04-26 Kombinatorische bibliotheken von monomerdomänen ATE472609T1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US28682301P 2001-04-26 2001-04-26
US33720901P 2001-11-19 2001-11-19
US33335901P 2001-11-26 2001-11-26
US37410702P 2002-04-18 2002-04-18
PCT/US2002/013257 WO2002088171A2 (en) 2001-04-26 2002-04-26 Combinatorial libraries of monomer domains

Publications (1)

Publication Number Publication Date
ATE472609T1 true ATE472609T1 (de) 2010-07-15

Family

ID=27501442

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02725828T ATE472609T1 (de) 2001-04-26 2002-04-26 Kombinatorische bibliotheken von monomerdomänen

Country Status (11)

Country Link
US (2) US20030082630A1 (de)
EP (1) EP1390535B1 (de)
JP (1) JP4369662B2 (de)
AT (1) ATE472609T1 (de)
AU (1) AU2002256371B2 (de)
CA (1) CA2444854A1 (de)
CY (1) CY1110808T1 (de)
DE (1) DE60236861D1 (de)
DK (1) DK1390535T3 (de)
PT (1) PT1390535E (de)
WO (1) WO2002088171A2 (de)

Families Citing this family (182)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050089932A1 (en) * 2001-04-26 2005-04-28 Avidia Research Institute Novel proteins with targeted binding
US20050048512A1 (en) * 2001-04-26 2005-03-03 Avidia Research Institute Combinatorial libraries of monomer domains
US20040175756A1 (en) * 2001-04-26 2004-09-09 Avidia Research Institute Methods for using combinatorial libraries of monomer domains
US20030157561A1 (en) * 2001-11-19 2003-08-21 Kolkman Joost A. Combinatorial libraries of monomer domains
US7591994B2 (en) 2002-12-13 2009-09-22 Immunomedics, Inc. Camptothecin-binding moiety conjugates
US8877901B2 (en) 2002-12-13 2014-11-04 Immunomedics, Inc. Camptothecin-binding moiety conjugates
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
US20040067532A1 (en) 2002-08-12 2004-04-08 Genetastix Corporation High throughput generation and affinity maturation of humanized antibody
US7563600B2 (en) 2002-09-12 2009-07-21 Combimatrix Corporation Microarray synthesis and assembly of gene-length polynucleotides
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
CA2432972A1 (en) * 2003-07-04 2005-01-04 Jeak L. Ding Sushi peptides, processes for making and uses thereof
CN101018559A (zh) * 2004-06-17 2007-08-15 安姆根山景公司 c－MET激酶结合蛋白
US20060008844A1 (en) * 2004-06-17 2006-01-12 Avidia Research Institute c-Met kinase binding proteins
CA2585717A1 (en) 2004-10-27 2006-05-04 Medimmune Inc. Modulation of antibody specificity by tailoring the affinity to cognate antigens
EP1824796A4 (de) * 2004-11-16 2010-02-17 Avidia Res Inst Proteingerüste und ihre verwendung
AU2005332022A1 (en) * 2004-11-16 2006-11-30 Avidia Research Institute Protein scaffolds and uses therof
ES2376586T3 (es) * 2005-01-03 2012-03-15 F. Hoffmann-La Roche Ag Método de identificación de un �?cido nucleico que codifica una estructura tipo hemopexina que se une de forma espec�?fica a una molécula diana predeterminada.
AU2006204459B2 (en) * 2005-01-05 2012-11-01 F-Star Therapeutics Limited Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions
CA2605145A1 (en) * 2005-04-26 2006-11-02 Sandoz Ag Affinity ligands
AU2011253661B2 (en) * 2005-04-26 2013-06-13 Boehringer Ingelheim Rcv Gmbh & Co Kg Production of recombinant proteins by autoproteolytic cleavage of a fusion protein
JP2007008926A (ja) * 2005-05-31 2007-01-18 Canon Inc 標的物質捕捉分子
JP2007008925A (ja) * 2005-05-31 2007-01-18 Canon Inc 標的物質捕捉分子
US20060286047A1 (en) * 2005-06-21 2006-12-21 Lowe David J Methods for determining the sequence of a peptide motif having affinity for a substrate
US7820790B2 (en) 2005-07-13 2010-10-26 Amgen Mountain View Inc. IL-6 binding proteins
CA2614186A1 (en) * 2005-07-13 2007-01-18 Amgen Mountain View Inc. Il-6 binding proteins
PT1973559E (pt) 2005-11-23 2013-02-19 Acceleron Pharma Inc Antagonistas de activina-actriia e utilizações para promover o crescimento ósseo
EP2674440B1 (de) 2005-12-16 2019-07-03 IBC Pharmaceuticals, Inc. Polyvalente bioaktive anordnungen auf immunglobulinbasis
GB2433591A (en) * 2005-12-20 2007-06-27 Sharp Kk Method for functionalising a hydrophobic substrate
GB2433505A (en) * 2005-12-20 2007-06-27 Sharp Kk Capture agents for binding a ligand
GB2433506A (en) * 2005-12-20 2007-06-27 Sharp Kk A method of producing a multimeric capture agent
US20080107597A1 (en) * 2006-01-12 2008-05-08 Anaptys Biosciences, Inc. Isolation of antibodies that cross-react and neutralize rankl originating from multiple species
EP1844788B1 (de) * 2006-04-13 2010-07-14 Bio Life Science Forschungs- und Entwicklungsges.m.b.H. HER-2/neu Multipeptidimpfstoff
WO2007136834A2 (en) * 2006-05-19 2007-11-29 Codon Devices, Inc. Combined extension and ligation for nucleic acid assembly
AT503889B1 (de) 2006-07-05 2011-12-15 Star Biotechnologische Forschungs Und Entwicklungsges M B H F Multivalente immunglobuline
EP2423332A1 (de) 2006-08-25 2012-02-29 Oncotherapy Science, Inc. Prognosemarker und therapeutische Targets für Lungenkrebs
US8053191B2 (en) * 2006-08-31 2011-11-08 Westend Asset Clearinghouse Company, Llc Iterative nucleic acid assembly using activation of vector-encoded traits
US20110182904A1 (en) 2006-09-05 2011-07-28 Deborah Zimmerman Antibodies to bone morphogenic proteins and receptors therefor and methods for their use
AR063086A1 (es) 2006-10-02 2008-12-23 Medarex Inc Anticuerpos humanos que se unen a cxcr4 y usos de los mismos
JP2010507099A (ja) * 2006-10-16 2010-03-04 ザ アリゾナ ボード オブ リージェンツ ア ボディ コーポレイト オブ ザ ステイト オブ アリゾナ アクティング フォー アンド オン ビハーフ オブ アリゾナ ステイト ユニバーシティー 合成抗体
JP5537946B2 (ja) 2006-11-22 2014-07-02 ブリストル−マイヤーズ スクイブ カンパニー Ｉｇｆ−ｉｒを含むチロシンキナーゼ受容体に対する改変タンパク質に基づく標的治療薬
ES2678060T3 (es) 2006-12-01 2018-08-08 E. R. Squibb & Sons, L.L.C. Anticuerpos, en particular, anticuerpos humanos, que se unen a CD22 y usos de los mismos
CL2007003622A1 (es) 2006-12-13 2009-08-07 Medarex Inc Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales.
WO2008076368A2 (en) * 2006-12-13 2008-06-26 Codon Devices, Inc. Fragment-rearranged nucleic acids and uses thereof
CN105797135A (zh) 2006-12-18 2016-07-27 阿塞勒隆制药公司 活化素-actrii拮抗剂及在提高红细胞水平中的用途
TWI584815B (zh) 2007-02-01 2017-06-01 艾瑟勒朗法瑪公司 活化素-ＡｃｔＲＩＩａ拮抗劑及其治療或預防乳癌之用途
TWI606062B (zh) 2007-02-09 2017-11-21 艾瑟勒朗法瑪公司 包含ＡｃｔＲＩＩａ-Ｆｃ融合蛋白的醫藥組合物；ＡｃｔＲＩＩａ-Ｆｃ融合蛋白於治療或預防與癌症相關的骨質流失之用途；ＡｃｔＲＩＩａ-Ｆｃ融合蛋白於治療或預防多發性骨髓瘤之用途
AR065368A1 (es) 2007-02-15 2009-06-03 Astrazeneca Ab Anticuerpos para moleculas de ige
AU2008218925A1 (en) 2007-02-20 2008-08-28 Anaptysbio, Inc. Somatic hypermutation systems
IN2009DN05758A (de) 2007-03-12 2015-07-24 Esbatech Ag
CN103694351A (zh) 2007-06-05 2014-04-02 耶鲁大学 受体酪氨酸激酶抑制剂及其使用方法
KR101530723B1 (ko) 2007-06-25 2015-06-22 에스바테크 - 어 노바티스 컴파니 엘엘씨 단일 쇄 항체의 서열에 기초한 공학처리 및 최적화
CN111253484A (zh) 2007-06-25 2020-06-09 艾斯巴技术-诺华有限责任公司 修饰抗体的方法和具有改善的功能性质的修饰抗体
CN101802006B (zh) 2007-06-26 2013-08-14 F-星生物技术研究与开发有限公司 展示结合剂
KR20100075858A (ko) 2007-08-24 2010-07-05 온코세라피 사이언스 가부시키가이샤 암 관련 유전자，ｃｄｃａ５，ｅｐｈａ７，ｓｔｋ３１ 및 ｗｄｈｄ１
TW200920405A (en) 2007-08-24 2009-05-16 Oncotherapy Science Inc PKIB and NAALADL2 for target genes of prostate cancer therapy and diagnosis
EP2198021A4 (de) 2007-08-24 2011-01-19 Oncotherapy Science Inc Ebi3, dlx5, nptx1 und cdkn3 für zielgene der lungenkrebstherapie und -diagnose
US12529164B2 (en) 2007-09-14 2026-01-20 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
EP2193146B1 (de) 2007-09-14 2016-05-25 Adimab, LLC Synthetische antikörperbibliotheken mit rationalem design und ihre verwendung
CN107412734A (zh) 2007-09-18 2017-12-01 阿塞勒隆制药公司 活化素‑actriia拮抗剂和减少或抑制fsh分泌的用途
KR20100128291A (ko) 2008-02-14 2010-12-07 브리스톨-마이어스 스큅 컴퍼니 Ｅｇｆｒ에 결합하는 조작된 단백질을 기초로 하는 표적화된 치료제
EP2113255A1 (de) 2008-05-02 2009-11-04 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Zytotoxisches Immunglobulin
AR071874A1 (es) 2008-05-22 2010-07-21 Bristol Myers Squibb Co Proteinas de dominio de armazon basadas en fibronectina multivalentes
MX346024B (es) 2008-06-25 2017-03-02 Esbatech Alcon Biomed Res Unit Optimización de solubilidad de inmuno-aglutinantes.
CA2729096C (en) 2008-06-26 2020-04-28 Acceleron Pharma Inc. Methods for dosing an actriib antagonist and monitoring of treated patients
EP2318028B1 (de) 2008-06-26 2020-02-19 Acceleron Pharma Inc. Antagonisten von löslichem activin-actriia und verwendungen zur erhöhung der anzahl roter blutkörperchen
CN102177438A (zh) 2008-07-25 2011-09-07 理查德·W·瓦格纳 蛋白筛选方法
KR101127476B1 (ko) * 2008-08-11 2012-03-23 아주대학교산학협력단 크링글 도메인의 구조에 기반한 단백질 골격 라이브러리 및 그 용도
WO2010021720A1 (en) 2008-08-19 2010-02-25 Nektar Therapeutics Conjugates of small-interfering nucleic acids
US20100082438A1 (en) * 2008-10-01 2010-04-01 Ronnie Jack Garmon Methods and systems for customer performance scoring
EP2349235A1 (de) * 2008-11-07 2011-08-03 Triact Therapeutics, Inc. Verwendung von catecholbutan-derivaten in der krebstherapie
TWI496582B (zh) 2008-11-24 2015-08-21 必治妥美雅史谷比公司 雙重專一性之ｅｇｆｒ／ｉｇｆｉｒ結合分子
US20120058131A1 (en) 2009-01-21 2012-03-08 Oxford Biotherapeutics Ltd Pta089 protein
PT3903829T (pt) 2009-02-13 2023-06-02 Immunomedics Inc Imunoconjugados com uma ligação intracelular clivável
CN102341412B (zh) 2009-03-05 2018-01-05 梅达雷克斯有限责任公司 特异于cadm1 的全人抗体
EP3058986B1 (de) 2009-03-30 2018-05-09 Acceleron Pharma Inc. Bmp-alk3-antagonisten und ihre verwendung zur förderung des knochenwachstums
ES2574236T3 (es) 2009-04-20 2016-06-16 Oxford Biotherapeutics Ltd Anticuerpos específicos para cadherina-17
JP5746174B2 (ja) 2009-08-17 2015-07-08 トラコン ファーマシューティカルズ、インコーポレイテッド 抗エンドグリン抗体及び抗ｖｅｇｆ剤を用いる癌の併用療法
US8221753B2 (en) 2009-09-30 2012-07-17 Tracon Pharmaceuticals, Inc. Endoglin antibodies
CN102781518A (zh) 2009-09-09 2012-11-14 阿塞勒隆制药公司 Actriib拮抗剂及其给药和用途
EP2470569A1 (de) 2009-10-13 2012-07-04 Oxford Biotherapeutics Ltd. Antikörper gegen epha10
US20120282177A1 (en) 2009-11-02 2012-11-08 Christian Rohlff ROR1 as Therapeutic and Diagnostic Target
US10207240B2 (en) 2009-11-03 2019-02-19 Gen9, Inc. Methods and microfluidic devices for the manipulation of droplets in high fidelity polynucleotide assembly
EP2496944A2 (de) 2009-11-05 2012-09-12 Novartis AG Prädiktive biomarker für die progression von fibrose
WO2011066185A1 (en) 2009-11-25 2011-06-03 Gen9, Inc. Microfluidic devices and methods for gene synthesis
WO2011072266A2 (en) 2009-12-11 2011-06-16 Atyr Pharma, Inc. Aminoacyl trna synthetases for modulating hematopoiesis
WO2011085075A2 (en) 2010-01-07 2011-07-14 Gen9, Inc. Assembly of high fidelity polynucleotides
AU2011214465A1 (en) 2010-02-10 2012-08-30 Novartis Ag Methods and compounds for muscle growth
AU2011248625B2 (en) 2010-04-26 2017-01-05 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of cysteinyl-tRNA synthetase
CN103096911B (zh) 2010-04-27 2018-05-29 Atyr 医药公司 与异亮氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
CN103097524B (zh) 2010-04-28 2016-08-03 Atyr医药公司 与丙氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
US9068177B2 (en) 2010-04-29 2015-06-30 Atyr Pharma, Inc Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glutaminyl-tRNA synthetases
CN103118693B (zh) 2010-04-29 2017-05-03 Atyr 医药公司 与缬氨酰‑tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
CA2797374C (en) 2010-04-29 2021-02-16 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of asparaginyl trna synthetases
WO2011140135A2 (en) 2010-05-03 2011-11-10 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of methionyl-trna synthetases
TW201138808A (en) 2010-05-03 2011-11-16 Bristol Myers Squibb Co Serum albumin binding molecules
ES2623805T3 (es) 2010-05-03 2017-07-12 Atyr Pharma, Inc. Descubrimiento innovador de composiciones terapéuticas, de diagnóstico y de anticuerpos relacionadas con fragmentos de proteínas de fenilalanil-alfa-ARNt sintetasas
CN103096925A (zh) 2010-05-03 2013-05-08 Atyr医药公司 与精氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
AU2011248101B2 (en) 2010-05-04 2016-10-20 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of p38 multi-tRNA synthetase complex
CA2805086C (en) 2010-05-13 2020-10-20 Sarepta Therapeutics, Inc. Antisense modulation of interleukins 17 and 23 signaling
US8945541B2 (en) 2010-05-14 2015-02-03 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-beta-tRNA synthetases
WO2011150133A2 (en) 2010-05-26 2011-12-01 Bristol-Myers Squibb Company Fibronectin based scaffold proteins having improved stability
DK2591099T3 (da) 2010-07-09 2021-02-15 Bioverativ Therapeutics Inc Kimære koagulationsfaktorer
CN103118695B (zh) 2010-07-12 2016-08-03 Atyr医药公司 与甘氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的发现
EP3000883B8 (de) 2010-11-12 2018-02-28 Gen9, Inc. Verfahren und vorrichtungen für nukleinsäuresynthese
US10457935B2 (en) 2010-11-12 2019-10-29 Gen9, Inc. Protein arrays and methods of using and making the same
TWI601722B (zh) 2011-03-11 2017-10-11 西建公司 ３-（５-胺基-２-甲基-４-氧基-４ｈ-喹唑啉-３-基）-六氫吡啶-２，６-二酮之固體型式及其醫藥組合物及用途
KR20140019364A (ko) 2011-03-11 2014-02-14 셀진 코포레이션 면역-관련 및 염증성 질환의 치료에 있어서의 3-(5-아미노-2-메틸-4-옥소퀴나졸린-3(4ｈ)-일)피페리딘-2-6-디온의 용도
JP6187777B2 (ja) 2011-06-13 2017-08-30 シーエスエル、リミテッド Ｇ−ｃｓｆｒに対する抗体およびその使用
RS55716B1 (sr) 2011-06-28 2017-07-31 Oxford Biotherapeutics Ltd Terapeutski i dijagnostički cilj
HUE034921T2 (en) 2011-06-28 2018-03-28 Oxford Biotherapeutics Ltd Antibodies against ADP-ribozil cyclase-2
IL280334B2 (en) 2011-08-26 2023-09-01 Gen9 Inc Preparations and methods for high-fidelity assembly of nucleic acids
EP2771351B1 (de) 2011-10-28 2017-06-14 Patrys Limited Pat-lm1-epitope und verfahren zu ihrer verwendung
WO2013074840A1 (en) 2011-11-15 2013-05-23 Allergan, Inc. Treatment of dry age related macular degeneration
WO2013106577A2 (en) 2012-01-10 2013-07-18 Biogen Idec Ma Inc. Enhancement of transport of therapeutic molecules across the blood brain barrier
JP6170077B2 (ja) 2012-02-16 2017-07-26 エータイアー ファーマ， インコーポレイテッド 自己免疫および炎症疾患を処置するためのヒスチジルｔＲＮＡ合成酵素
US9150853B2 (en) 2012-03-21 2015-10-06 Gen9, Inc. Methods for screening proteins using DNA encoded chemical libraries as templates for enzyme catalysis
CN104603286B (zh) 2012-04-24 2020-07-31 Gen9股份有限公司 在体外克隆中分选核酸和多重制备物的方法
WO2013175276A1 (en) 2012-05-23 2013-11-28 Argen-X B.V Il-6 binding molecules
WO2014004393A1 (en) 2012-06-25 2014-01-03 Gen9, Inc. Methods for nucleic acid assembly and high throughput sequencing
GB201213652D0 (en) 2012-08-01 2012-09-12 Oxford Biotherapeutics Ltd Therapeutic and diagnostic target
KR102266510B1 (ko) 2012-08-09 2021-06-16 셀진 코포레이션 3-(4-((4-모르포리노메틸)벤질)옥시)-1-옥소이소인돌린-2-일)피페리딘-2,6-디온을 이용한 암의 치료방법
HRP20200836T1 (hr) 2012-08-09 2020-08-07 Celgene Corporation Liječenje bolesti povezanih s imunitetom i upalnih bolesti
US9221788B2 (en) 2012-08-09 2015-12-29 Celgene Corporation Salts and solid forms of (S)-3-(4- (4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and compositions comprising and methods of using the same
WO2014023315A1 (en) 2012-08-10 2014-02-13 Aarhus Universitet Multimerization through beta-strand swapping in ccp domains
UA115789C2 (uk) 2012-09-05 2017-12-26 Трейкон Фармасутікалз, Інк. Композиція антитіла до cd105 та її застосування
WO2014055784A1 (en) 2012-10-03 2014-04-10 Zymeworks Inc. Methods of quantitating heavy and light chain polypeptide pairs
IL267663B (en) 2012-10-24 2022-09-01 Celgene Corp A biomarker for use in the treatment of anemia
EP2914277B1 (de) 2012-11-02 2017-09-13 Celgene Corporation Activin-actrii-antagonisten und verwendungen zur behandlung von knochen- und anderen erkrankungen
RU2670943C9 (ru) 2012-11-08 2018-11-26 Илэвэн Байотерапьютикс, Инк. Антагонисты ил-6 и их применение
CA3177936A1 (en) 2012-12-13 2014-06-19 Immunomedics, Inc. Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
GB201302447D0 (en) 2013-02-12 2013-03-27 Oxford Biotherapeutics Ltd Therapeutic and diagnostic target
CA2941010A1 (en) 2013-02-26 2014-09-04 Triact Therapeutics, Inc. Cancer therapy
WO2014133855A1 (en) 2013-02-28 2014-09-04 Caprion Proteomics Inc. Tuberculosis biomarkers and uses thereof
EP2774930A1 (de) 2013-03-07 2014-09-10 Aptenia S.R.L. Metallocenverbindungen und markierte Moleküle damit für In-vivo-Bildgebung
US9157910B2 (en) 2013-03-15 2015-10-13 Abbott Laboratories Assay with increased dynamic range
US9005901B2 (en) 2013-03-15 2015-04-14 Abbott Laboratories Assay with internal calibration
CN110041427B (zh) 2013-03-15 2023-05-23 本质生命科学有限公司 抗铁调素抗体及其用途
CN113683695A (zh) 2013-08-02 2021-11-23 辉瑞公司 抗cxcr4抗体及抗体-药物缀合物
US9381246B2 (en) 2013-09-09 2016-07-05 Triact Therapeutics, Inc. Cancer therapy
KR102339724B1 (ko) 2013-11-28 2021-12-17 씨에스엘 리미티드 신장병증의 치료 방법
JP6553618B2 (ja) 2013-12-18 2019-07-31 シーエスエル リミティド 創傷を治療する方法
MX378753B (es) 2014-03-20 2025-03-10 Bristol Myers Squibb Co Dominios de fibronectina tipo iii que se unen a albúmina de suero.
ES2903029T3 (es) 2014-07-03 2022-03-30 Univ Yale La inhibición de DICKKOPF2 (DKK2) suprime la formación de tumores
CA2957250A1 (en) 2014-08-15 2016-02-18 Adynxx, Inc. Oligonucleotide decoys for the treatment of pain
NZ730186A (en) 2014-09-22 2020-04-24 Intrinsic Lifesciences Llc Humanized anti-hepcidin antibodies and uses thereof
AU2015324924B2 (en) 2014-10-01 2021-07-01 Medimmune, Llc Method of conjugating a polypeptide
MA41052A (fr) 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
ES3051832T3 (en) 2014-11-07 2025-12-30 F Hoffmann La Roche Ltd Improved il-6 antibodies
WO2016073894A1 (en) 2014-11-07 2016-05-12 Eleven Biotherapeutics, Inc. Therapeutic agents with increased ocular retention
US10155820B2 (en) 2014-11-12 2018-12-18 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof
US9926375B2 (en) 2014-11-12 2018-03-27 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof
TWI730949B (zh) 2014-12-03 2021-06-21 美商西建公司 活化素-ａｃｔｒｉｉ拮抗劑及治療貧血之用途
EP4190805A3 (de) 2015-05-20 2023-08-16 Celgene Corporation In-vitro-zellkulturverfahren zur beta-thalassämie mittels fallen von activin-typ-ii-rezeptor-liganden
EP3313443B9 (de) 2015-06-25 2023-10-04 Immunomedics, Inc. Kombination von anti-hla-dr- oder anti-trop-2-antikörpern mit mikrotubuli-inhibitoren, parp-inhibitoren, bruton-kinase-inhibitoren oder phosphoinositol-3-kinase-inhibitoren zur signifikanten verbesserung des therapeutischen ergebnisses bei krebs
CN108290941A (zh) 2015-09-23 2018-07-17 百时美施贵宝公司 快解离速率的血清白蛋白结合性纤连蛋白iii型结构域
JP6921067B2 (ja) 2015-10-28 2021-08-18 イエール ユニバーシティ ヒト化抗Ｄｋｋ２抗体およびその使用方法
EP3380514A4 (de) 2015-11-27 2019-05-22 CSL Limited Gdf131-bindende proteine und verwendungen davon
SG11201804367PA (en) 2015-12-02 2018-06-28 Celgene Corp Cycling therapy using 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione
KR20180116359A (ko) 2016-02-23 2018-10-24 세센 바이오, 아이엔씨. 인터루킨-6의 길항제 제제 및 이의 용도
CA3034105A1 (en) 2016-09-23 2018-03-29 Csl Limited Coagulation factor binding proteins and uses thereof
US20180258064A1 (en) 2017-03-07 2018-09-13 Celgene Corporation Solid forms of 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione, and their pharmaceutical compositions and uses
AR111963A1 (es) 2017-05-26 2019-09-04 Univ California Método y moléculas
PT3681911T (pt) 2017-09-11 2024-12-18 Univ Monash Proteínas de ligação ao recetor humano da trombina, par4
EP3697812A4 (de) 2017-10-18 2021-09-22 CSL Limited Menschliche serumalbuminvarianten und ihre verwendungen
AU2018377856B2 (en) 2017-11-29 2025-01-09 Csl Limited Method of treating or preventing ischemia-reperfusion injury
WO2019178645A1 (en) 2018-03-23 2019-09-26 Csl Limited Method of treating asthma
WO2020176553A1 (en) * 2019-02-25 2020-09-03 Sense Therapeutics Inc. Intracellular mutation targeting therapy
AU2020235455A1 (en) 2019-03-08 2021-10-28 Oxford Genetics Limited Method of selecting for antibodies
GB201903233D0 (en) 2019-03-08 2019-04-24 Oxford Genetics Ltd Method of selecting for antibodies
WO2020198731A2 (en) 2019-03-28 2020-10-01 Danisco Us Inc Engineered antibodies
IL294045A (en) 2019-12-20 2022-08-01 Hudson Inst Med Res Proteins that bind to cxcl10 and their uses
US12583929B2 (en) 2020-06-04 2026-03-24 CSL Innovation Pty Ltd Method of treating acute respiratory distress syndrome
WO2023034809A1 (en) 2021-08-30 2023-03-09 Lassen Therapeutics 1, Inc. Anti-il-11rα antibodies
US20250223326A1 (en) 2022-05-10 2025-07-10 Institut National de la Santé et de la Recherche Médicale Syncitin-1 fusion proteins and uses thereof for cargo delivery into target cells
US20260078376A1 (en) 2022-08-26 2026-03-19 Core Biotherapeutics, Inc. Oligonucleotides for the treatment of breast cancer
WO2024064646A1 (en) 2022-09-20 2024-03-28 Celgene Corporation Salts and solid forms of (s)- or racemic 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and methods of using the same
EP4608861A1 (de) 2022-10-24 2025-09-03 F. Hoffmann-La Roche AG Vorhersage der reaktion auf il-6-antagonisten
WO2024148243A1 (en) 2023-01-06 2024-07-11 Lassen Therapeutics 1, Inc. Anti-il-18bp antibodies
CN120858108A (zh) 2023-01-06 2025-10-28 拉森医疗公司 抗il-18bp抗体
CN120787238A (zh) 2023-01-06 2025-10-14 拉森医疗公司 用于治疗甲状腺眼病的抗IL-11Rα抗体
WO2025007195A1 (en) 2023-07-05 2025-01-09 CSL Innovation Pty Ltd Methods of treating or preventing a complication of sickle cell disease

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE64618T1 (de) * 1982-03-15 1991-07-15 Schering Corp Hybride dns, damit hergestellte bindungszusammensetzung und verfahren dafuer.
US5258498A (en) * 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5663143A (en) * 1988-09-02 1997-09-02 Dyax Corp. Engineered human-derived kunitz domains that inhibit human neutrophil elastase
US5473039A (en) * 1989-08-18 1995-12-05 The Scripps Research Institute Polypeptide analogs of apolipoprotein E, diagnostic systems and methods using the analogs
US5427908A (en) * 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US6329507B1 (en) * 1992-08-21 2001-12-11 The Dow Chemical Company Dimer and multimer forms of single chain polypeptides
AU5670194A (en) 1992-11-20 1994-06-22 Enzon, Inc. Linker for linked fusion polypeptides
SE9400088D0 (sv) * 1994-01-14 1994-01-14 Kabi Pharmacia Ab Bacterial receptor structures
JP3659261B2 (ja) * 1994-10-20 2005-06-15 モルフォシス・アクチェンゲゼルシャフト 組換体タンパク質の多機能性複合体への標的化ヘテロ結合
CA2222055A1 (en) * 1995-05-23 1996-11-28 Morphosys Gesellschaft Fur Proteinoptimierung Mbh Multimeric proteins
AUPO591797A0 (en) * 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
EP1005569A2 (de) * 1997-08-01 2000-06-07 MorphoSys AG Verfahren und phage für die identifizierung von multimere polypeptidkomplexkodierende nukleinsäuresequenzen
US6030771A (en) * 1997-08-25 2000-02-29 Centers For Disease Control And Prevention Mosaic protein and restriction endonuclease assisted ligation method for making the same
GB9722131D0 (en) * 1997-10-20 1997-12-17 Medical Res Council Method
US20020131972A1 (en) * 1998-05-21 2002-09-19 Daniel Sem Multi-partite ligands and methods of identifying and using same
US6818418B1 (en) * 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
ES2313886T3 (es) * 1999-03-16 2009-03-16 The Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services Nueva proteina quimerica para la prevencion y tratamiento de infeccion por hiv.
AUPQ339899A0 (en) * 1999-10-13 1999-11-04 University Of Queensland, The Novel molecules
DE10053224A1 (de) * 2000-10-26 2002-05-08 Univ Goettingen Georg August Verfahren zur Exposition von Peptiden und Polypeptiden auf der Zelloberfläche von Bakterien
US20040171544A1 (en) * 2001-04-24 2004-09-02 Barker Nicholas P. Trefoil domain-containing polypeptides and uses thereof

Also Published As

Publication number Publication date
CA2444854A1 (en) 2002-11-07
CY1110808T1 (el) 2012-05-23
WO2002088171A2 (en) 2002-11-07
EP1390535A2 (de) 2004-02-25
DK1390535T3 (da) 2010-12-06
EP1390535A4 (de) 2005-01-05
JP4369662B2 (ja) 2009-11-25
PT1390535E (pt) 2010-10-04
AU2002256371B2 (en) 2008-01-10
US20050221384A1 (en) 2005-10-06
WO2002088171A3 (en) 2003-05-08
DE60236861D1 (de) 2010-08-12
EP1390535B1 (de) 2010-06-30
JP2005519579A (ja) 2005-07-07
US20030082630A1 (en) 2003-05-01

Similar Documents

Publication Publication Date Title
ATE472609T1 (de) Kombinatorische bibliotheken von monomerdomänen
WO2004044011A3 (en) Combinatorial libraries of monomer domains
WO2005040229A3 (en) Ldl receptor class a and egf domain monomers and multimers
DK0873340T3 (da) Heterocyklisk substituerede cyclopentanforbindelser
DE69730235D1 (de) Neuartige Verfahren und Zusammensetzungen zur Entdeckung von neuen multimerischen Molekülen, basierend auf einer kombinatorisichen Bibliothek
ATE376026T1 (de) Klebstoffzusammensetzungen mit selbstorganisierenden molekülen, klebstoffe, gegenstände und verfahren
CY1109462T1 (el) Συνθεση και διαδικασια εκχυλιση του διαλυτη μεταλλων χρησιμοποιωντας τους παραγοντες εκχυλισης αλδοξιμη ή κετοξιμη
DK1694792T3 (da) Sammensætning og fremgangsmåder til overtræk af konservesdåser
DK0693073T3 (da) Bicykliske ansamyciner og deres anvendelse som antitumormidler
ATE269295T1 (de) Btk inhibitoren und verfahren zur identifizierung und verwendung
EA200601124A1 (ru) Противовирусные фармацевтические композиции
DE69634127D1 (de) Zellfreie synthese von polyketiden
TR200101858T2 (tr) JNK protein kinaz inhibitörleri olarak 4-ariloksindoller
ATE470306T1 (de) Verfahren für netzwerkadressenevaluierung und zugriff
DK1073905T3 (da) Fremgangsmåder til selektering af internaliserings-antistoffer
CY1105758T1 (el) Τροποποιημενη απιμιναση αργινινης
DE50115349D1 (de) Verfahren zur selektion von partikeln
DE69930067D1 (de) Darstellung von Netzinformationen
ATE553185T1 (de) Expressionskassette und vektor zur transienten oder stabilen expression exogener moleküle
NO20075140L (no) Fremgangsmater og preparater for modulering av vaskulaer integritet
WO2004101764A3 (en) Methods of modulating metastasis and skeletal related events resulting from metastases
BR0315178A (pt) Eritropoietina: remodelagem e glicoconjugação de eritropoietina
ATE513040T1 (de) Zinkfingerdomänenbibliotheken
DE60312895D1 (de) Emulsionen mit oberflächenmodifizierten organischen molekülen
Macaulay Prosody and intonation in Formosan languages

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1390535

Country of ref document: EP